876results about "Veterinary vaccine" patented technology

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The invention relates to the technical field of mRNA vaccines, and discloses a feline infectious peritonitis mRNA vaccine as well as a preparation method and application thereof. The feline infectious peritonitis mRNA vaccine comprises mRNA molecules; the mRNA molecule comprises an FIBV-S protein coding sequence as shown in SEQ ID NO: 6. According to the invention, the mRNA sequence for coding the natural FIBV-S protein is modified, so that the FIBV-S protein obtained by translation can be stably maintained at the prefusion conformation and has higher immunogenicity, thereby endowing the mRNA vaccine with a better immune effect and being beneficial to the prevention of feline infectious peritonitis.

The invention discloses chicken infectious anemia virus-like particles as well as a preparation method and application thereof. The invention discloses a virus-like particle vaccine for preventing chicken infectious anemia. The virus-like particle vaccine comprises VP1 and VP2 proteins of chicken infectious anemia viruses. Chicken infectious anemia VP1 and VP2 proteins are expressed by using a baculovirus expression system, immunoblotting shows that the two proteins are successfully expressed in sf9 cells, electron microscope observation finds that the expressed proteins can be autonomously assembled into complete chicken infectious anemia virus-like particles, and the chicken infectious anemia virus-like particles have a space structure similar to that of an original virus and can be used for preparing chicken infectious anemia virus-like particles. Meanwhile, the virus-like particles have the advantages of high titer, high safety, capability of stimulating humoral immunity and cellular immunity and the like. The preparation method disclosed by the invention is simple, can be used for preparing the antigen protein of the chicken infectious anemia virus on a large scale, is high in expression quantity and short in time consumption, greatly reduces the production cost, and is suitable for large-scale production.

The invention provides a bovine parainfluenza virus type 3 QL3 strain, and the preservation number of the bovine parainfluenza virus type 3 QL3 strain is CGMCC No.46469. The invention also provides a bovine parainfluenza inactivated vaccine containing the bovine parainfluenza virus type 3 QL3 strain and purified F protein and HN protein of the QL3 strain. The novel bovine parainfluenza virus type 3 inactivated vaccine is obtained by optimizing the antigen components of the bovine parainfluenza virus type 3 inactivated vaccine, and high-level neutralizing antibodies can be generated after immunizing cattle; the safety of the vaccine is improved through process optimization. Safety and potency test results show that after the inactivated vaccine is used for immunizing cattle, no adverse reaction exists, and high-level neutralizing antibodies are generated. Results show that the immune effect of the bovine parainfluenza virus type 3 inactivated vaccine can be improved.

The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.

The invention provides a culture method of avian encephalomyelitis virus, and belongs to the technical field of biology. According to the method, chicken lymphoma suspension cells are adopted to culture the avian encephalomyelitis virus, the titer of the obtained avian encephalomyelitis virus reaches 106.5-6.8 EID50 / 0.2 mL, and the method is short in culture period, high in production efficiency, low in cost, controllable in quality and capable of being used for large-scale industrial production.

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention relates to low dose compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens, and the antibodies generated. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences or antibodies, and to methods for treating and preventing an infection in animals and mammals such as humans.

The invention belongs to the field of veterinary biological products, and particularly relates to a chicken infectious laryngotracheitis recombinant subunit vaccine as well as a preparation method and application thereof. A core antigen of the vaccine is a recombinant gB trimer glycoprotein (gB-Trimer) modified by genetic engineering, and the protein successfully locks a prefusion conformation with the strongest immunogenicity of the gB protein through strategies of truncation, trimerization motif splicing, dual-stability mutation and the like. The vaccine prepared by the invention can stimulate rapid and lasting neutralizing antibody response, provide 100% clinical protection and effectively block replication and detoxification of the ILTV, has extremely high biological safety compared with a traditional live vaccine, completely eliminates risks of poison dispersion and enhancement, and provides a safe and efficient novel solution for prevention and control of the ILTV.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a water-in-oil-in-water adjuvant, a veterinary vaccine and a preparation method thereof.The water-in-oil-in-water adjuvant is prepared from, by weight, 0.5%-7.5% of a hydrophilic composite surfactant, 0.6%-9.8% of an oleophylic composite surfactant, 70%-85% of mineral oil and the balance water; and the mineral oil also comprises the following components in concentration: a reinforcing agent of 0.45-0.9 g / ml and a stabilizing agent of 2-6.9 g / L, wherein the water-in-oil-in-water adjuvant forms a gelatinous structure under the regulation of the stabilizer and is a non-Newtonian fluid of which the viscosity is not higher than 25cp; the adjuvant shows the non-flowing fluid characteristic through the stabilizer, the rheological property of the produced vaccine is enhanced, the stability of the vaccine is improved, on the premise that the hydrophilic surfactant and the oleophylic surfactant are balanced, the natural polymer enhancer is added, and on the premise that the adjuvant viscosity is reduced and granuloma side reaction is not prone to being generated, the stability of the vaccine is improved. Short-term immunity and long-term immunity can be induced at the same time, and the application of the water-in-oil-in-water adjuvant in the field of veterinary vaccines is expanded.

The invention relates to the technical field of biological medicine, in particular to a vaccine adjuvant containing saponin and a preparation method of the vaccine adjuvant. The vaccine adjuvant containing saponin is prepared from the following raw materials in percentage by mass: 0.05 to 0.2 percent of saponin components, 0.5 to 2.0 percent of phospholipid, 3 to 7 percent of oil phase, 0.5 to 2.5 percent of surfactant, 0.05 to 0.2 percent of antioxidant, 2.5 to 4.0 percent of trehalose, 0.1 to 0.5 percent of novel synergistic polymer and the balance of water for injection, according to the preparation method disclosed by the invention, an innovative preparation process of firstly preparing blank nanoemulsion and then loading saponin is adopted, and a stable protective layer is formed on the interface of the nanoemulsion, so that hemolytic groups of the saponin are effectively shielded, the toxic and side effects of the saponin are remarkably reduced, and the chemical stability of the saponin is protected. The adjuvant disclosed by the invention is good in stability, high in safety and strong in immune effect, and has a good clinical application prospect.

The invention discloses a mannose modified liposome gel microsphere oral delivery system based on cations and application of the mannose modified liposome gel microsphere oral delivery system. The oral delivery system comprises a core layer and a wrapping layer, the core layer is mannose modified cationic liposome loaded with a mucous membrane adjuvant retinoic acid and an antigen, and the wrapping layer is sodium alginate gel vulcanized and modified by cysteine. The mannose modified cationic liposome is prepared by coupling mannose on the surface of the cationic liposome, and the cysteine modified sodium alginate gel is used for protecting antigens in the core layer from being eroded by gastric juice, enhancing the adhesiveness of a delivery system in the intestinal tract and prolonging the retention time of the delivery system in the intestinal tract; in addition, the R-MLip can be expanded and released under the environment that the pH of the intestinal tract is increased. The inside of the gel microsphere of the oral delivery system shows a regular net-shaped structure and has abundant holes and channels, and the oral delivery system shows a good prospect in the aspect of enhancing mucous membrane and systemic immunity and possibly becomes a potential substitute of a traditional attenuated live vaccine in the future.

The invention provides an infectious bronchitis virus subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering vaccines. According to the chicken infectious bronchitis virus mutant protein disclosed by the invention, the amino acid sequence of the mutant protein is shown as SEQ ID NO.5. According to the avian infectious bronchitis virus subunit vaccine containing the recombinant avian infectious bronchitis virus mutant protein Kozak-IgKsp-IBV-M41-S-core-6His as an effective component, the glycosylation level of the vaccine is relatively high, the expression level is relatively stable, the virus return risk of a live vaccine does not exist, the safety is high, large-scale industrial preparation can be achieved, and the vaccine has good application prospects. The cost is low.

The invention discloses preparation and application of a rabies virus G protein mRNA vaccine freeze-drying preparation, and relates to the field of veterinary biological products. According to the invention, rabies virus G protein mRNA is prepared on a large scale through an in-vitro transcription technology, and an mRNA-LNP (lipid nanoparticle) delivery system is successfully constructed by adopting a microfluidic encapsulation process. Through freeze-drying protective agent formula screening (including cane sugar, trehalose and mannitol) and freeze-drying procedure parameter optimization (including pre-freezing temperature, main drying rate and secondary drying residual moisture control), the freeze-dried mRNA vaccine preparation which can stably exist under the condition of 4 DEG C is finally obtained.

The invention discloses a self-assembled ferritin nano antigen particle and application thereof in preparation of a duck hepatitis A vaccine. The VP1 part in the duck hepatitis A virus P1 protein is connected with the N end of a self-assembled ferritin nanoparticle subunit through a connecting sequence to obtain the fusion protein, and the amino acid sequence of the fusion protein is shown as SEQ ID NO.1; in order to improve the expression quantity or expression efficiency of the fusion protein in bombyx mori, a nucleotide sequence of a coding gene of the fusion protein is optimized and modified according to the codon preference of bombyx mori, and an optimized gene sequence with the nucleotide sequence shown as SEQ ID NO.2 is obtained; the fusion protein is subjected to single-site or multi-site mutation, the mutant with obviously improved titer is obtained through screening, and the soluble expression quantity of the mutant is obviously improved. According to the invention, a silkworm or insect cell eukaryotic expression system is used for expressing recombinant protein, and an expression product causes a neutralizing anti-duck hepatitis A virus antibody.

The invention provides a kit for detecting bovine viral diarrhea virus and application of the kit. According to the present invention, the BVDV E2 protein is optimized, the monoclonal antibody 3G5 capable of specifically identifying DVDV1 type and DVD2 type viruses is screened on the basis, and the monoclonal antibody not only can specifically identify the purified and expressed BVDV E2 protein, but also can specifically identify the BVDV in the natural virus infected MDBK cell. By preparing the monoclonal antibody of the BVDV-E2 protein, a series of BVDV immunological diagnostic reagents can be researched and developed, and the monoclonal antibody has important significance on BVDV diagnosis.

The invention relates to a preparation method of a Vero cell influenza virus vaccine, and belongs to the technical field of virus culture. In the culture of the influenza virus, red algae protein and soybean protein hydrolysate are added into a culture medium at the same time, the red algae protein and soybean protein hydrolysate are subjected to low-temperature ammonium sulfate precipitation and PD-10 desalination column purification, natural conformation is kept, integrin-FAK-Src and IGF-1R signal channels can be activated, and cell adhesion and proliferation are promoted; the latter contains soybean protein isolate, polysaccharide and RGD motif peptide, and can form an adhesion film on a substrate and mediate adhesion through integrin. According to the invention, the Vero cells and the recombinant plasmid are combined to improve cell adherence, metabolic homeostasis and oxidation resistance, so that the Vero cells grow at high density and efficiently replicate influenza viruses under a serum-free condition, the virus titer (TCID50) reaches 8.5 log10 / mL, and the Vero cells and the recombinant plasmid are suitable for industrial vaccine production.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

The present invention relates to vaccination against animal pathogens using alpha virus-replicon RNA particles and oil adjuvants. To vaccines and kits comprising said replicon particles and said oil adjuvant. The invention also relates to methods and uses for preparing and using the vaccine and the components of the kit.

The application belongs to the technical field of biotechnology, and particularly relates to a porcine epidemic diarrhea virus recombinant strain, a construction method and application. The S gene sequence of the existing epidemic porcine epidemic diarrhea virus PEDV CH / SX / 2016 strain is replaced by the S2015 gene sequence shown in SEQ ID NO. 1 to construct a PEDV CH / SX / 2016 strain infectious clone. A porcine epidemic diarrhea virus recombinant strain rCH / SX / 2016-S 2015 is successfully rescued by transfecting cells with a plasmid containing the infectious cDNA shown in SEQ ID NO. 4. The problem that the original strain cannot be successfully rescued by reverse genetics engineering is solved, and the recombinant virus strain rCH / SX / 2016-S 2015 has an activity comparable to that of the original strain, and can be used for preparing a PEDV diagnostic reagent and / or vaccine.

The present invention relates to attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 obtained by passaging the African swine fever virus (ASFV) in a rhesus monkey kidney cell-derived cell line, and uses thereof. The African swine fever virus ASFV-KOR.INJE.MEC-01.2022 naturally attenuated by cell adaptation according to the present invention possesses both safety and efficacy, and therefore it can be effectively utilized as an antigen in vaccine compositions for the prevention of African swine fever.

The invention provides a toxoplasma gondii gene deletion strain with an immune protection effect and application of the toxoplasma gondii gene deletion strain, and belongs to the technical field of veterinary parasitology, veterinary immunology and parasite molecular biology. According to the toxoplasma gondii gene deletion strain, a gamma-glutamyl hydrolase gene is deleted. The invention also provides a method for constructing the insect strain. The method comprises the following steps: constructing a circular plasmid pSAG1-Cas9-U6-sgGGH; constructing a repair template containing upstream and downstream homologous arms of the gamma-glutamyl hydrolase gene and a DHFR resistance gene; co-transfecting the annular plasmid and the repair template to a toxoplasma gondii ME49 strain; performing drug screening on pyrimethamine to obtain positive monoclone; and confirming that the GGH gene is completely knocked out through PCR (Polymerase Chain Reaction) detection, sequencing analysis and immunofluorescence detection. The toxoplasma gondii gene deletion strain can provide a remarkable protection effect on toxoplasma gondii infection and is high in safety.

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.

This invention discloses a candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine, its construction method, and its application. The candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine is *R. anatipestifer* strain CH-1. B739_RS01935-B739_RS07625 A candidate attenuated live vaccine strain with double gene deletion, deposited at the China Center for Type Culture Collection (CCTCC) on May 22, 2025, with accession number CCTCC NO: M20251080, at Wuhan University, Wuhan, China, has been deposited on that date. The attenuated live strain constructed in this invention showed no significant impact on the weight gain of ducklings after immunization, demonstrating good safety. Furthermore, the protection rate against challenge with the wild-type virulent RACH-1 strain reached 83.3% after immunization, indicating excellent immunoprotective efficacy.